PMID- 34514096
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211002
IS  - 2372-7705 (Print)
IS  - 2372-7705 (Electronic)
IS  - 2372-7705 (Linking)
VI  - 22
DP  - 2021 Sep 24
TI  - miR-1207-5p suppresses laryngeal squamous cell carcinoma progression by 
      downregulating SKA3 and inhibiting epithelial-mesenchymal transition.
PG  - 152-165
LID - 10.1016/j.omto.2021.08.001 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is the second most common head and neck 
      cancer. Previously, we discovered that miR-1207-5p was downregulated in LSCC. In 
      this study, the clinical significance, function, and mechanism of miR-1207-5p in 
      LSCC were investigated. Downregulation of miR-1207-5p was found to be strongly 
      linked to the malignant progression of LSCC. Functional studies revealed that 
      miR-1207-5p upregulation suppressed LSCC cell proliferation, invasion, migration, 
      and xenograft tumor growth. Bioinformatics analysis revealed that miR-1207-5p 
      target genes were involved in cell cycle regulation, proliferation, adhesion, and 
      the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Mechanistic studies 
      revealed that miR-1207-5p interacts directly with the 3' untranslated region of 
      spindle and kinetochore associated complex subunit 3 (SKA3) and downregulates 
      SKA3 expression. Furthermore, SKA3 was found to be overexpressed in LSCC, and its 
      high expression was associated with tumor progression and a poor prognosis. 
      Rescue experiments demonstrated that miR-1207-5p inhibited the malignant 
      phenotypes of LSCC via SKA3. Furthermore, miR-1207-5p upregulation or knockdown 
      of SKA3 inhibited the epithelial-mesenchymal transition (EMT). Collectively, 
      miR-1207-5p inhibited LSCC malignant progression by downregulating SKA3 and 
      preventing EMT. These findings provide new insights into the mechanism of LSCC 
      progression, as well as new potential biomarkers and therapeutic targets for LSCC 
      diagnosis and treatment.
CI  - (c) 2021 The Author(s).
FAU - Wu, Yongyan
AU  - Wu Y
AD  - General Hospital, Clinical Medical Academy, Shenzhen University, Shenzhen 518055, 
      Guangdong, China.
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi 
      Province Clinical Medical Research Center for Precision Medicine of Head and Neck 
      Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, 
      China.
AD  - Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical 
      University, Taiyuan 030001, Shanxi, China.
AD  - Department of Biochemistry & Molecular Biology, Shanxi Medical University, 
      Taiyuan 030001, Shanxi, China.
FAU - Dai, Fengsheng
AU  - Dai F
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi 
      Province Clinical Medical Research Center for Precision Medicine of Head and Neck 
      Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, 
      China.
FAU - Zhang, Yuliang
AU  - Zhang Y
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi 
      Province Clinical Medical Research Center for Precision Medicine of Head and Neck 
      Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, 
      China.
FAU - Zheng, Xiwang
AU  - Zheng X
AD  - General Hospital, Clinical Medical Academy, Shenzhen University, Shenzhen 518055, 
      Guangdong, China.
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi 
      Province Clinical Medical Research Center for Precision Medicine of Head and Neck 
      Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, 
      China.
FAU - Li, Li
AU  - Li L
AD  - Department of Cell biology and Genetics, Basic Medical School of Shanxi Medical 
      University, Taiyuan 030001, Shanxi, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical 
      University, Taiyuan 030001, Shanxi, China.
FAU - Cao, Jimin
AU  - Cao J
AD  - Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical 
      University, Taiyuan 030001, Shanxi, China.
FAU - Gao, Wei
AU  - Gao W
AD  - General Hospital, Clinical Medical Academy, Shenzhen University, Shenzhen 518055, 
      Guangdong, China.
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi 
      Province Clinical Medical Research Center for Precision Medicine of Head and Neck 
      Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, 
      China.
AD  - Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical 
      University, Taiyuan 030001, Shanxi, China.
AD  - Department of Cell biology and Genetics, Basic Medical School of Shanxi Medical 
      University, Taiyuan 030001, Shanxi, China.
LA  - eng
PT  - Journal Article
DEP - 20210819
PL  - United States
TA  - Mol Ther Oncolytics
JT  - Molecular therapy oncolytics
JID - 101666776
PMC - PMC8416975
OTO - NOTNLM
OT  - epithelial-mesenchymal transition
OT  - invasion
OT  - laryngeal squamous cell carcinoma
OT  - miR-1207-5p
OT  - migration
OT  - proliferation
COIS- The authors declare no competing interests.
EDAT- 2021/09/14 06:00
MHDA- 2021/09/14 06:01
PMCR- 2021/08/19
CRDT- 2021/09/13 06:58
PHST- 2021/04/07 00:00 [received]
PHST- 2021/08/12 00:00 [accepted]
PHST- 2021/09/13 06:58 [entrez]
PHST- 2021/09/14 06:00 [pubmed]
PHST- 2021/09/14 06:01 [medline]
PHST- 2021/08/19 00:00 [pmc-release]
AID - S2372-7705(21)00112-1 [pii]
AID - 10.1016/j.omto.2021.08.001 [doi]
PST - epublish
SO  - Mol Ther Oncolytics. 2021 Aug 19;22:152-165. doi: 10.1016/j.omto.2021.08.001. 
      eCollection 2021 Sep 24.